Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Found this on MSN:

<<Immunomedics Awarded Two U.S. Patents for Therapeutic Radiopharmaceuticals


February 14, 2000 07:30 AM
MORRIS PLAINS, N.J., Feb. 14 /PRNewswire/ -- Immunomedics, Inc. IMMU today announced that the U.S. Patent and Trademark Office has awarded the Company two patents covering novel therapeutic radiopharmaceuticals.
Patent 5,976,492 describes new methods of linking phosphorus-32 and phosphorus-33 to diverse disease-targeting proteins, such that they retain the ability to bind to abnormal cells. Phosphorus-32 is currently being used clinically in the therapy of ovarian cancer and a malignancy of red blood cells, polycythemia vera. Phosphorus-32 is inexpensive, readily available, and useful in an outpatient setting.

"The reason that radioactive phosphorus has received relatively little attention for targeted radiotherapy applications has been the difficulty of linking it to proteins; most of the methods are non-specific, slow, and inefficient," commented Dr. David M. Goldenberg, Chairman and CEO of Immunomedics. "This new invention has overcome these problems, and will allow radioactive phosphorus to be linked to a variety of disease-targeting proteins, such as antibodies, lymphokines, cytokines, growth factors, and other molecules, thus generating new categories of therapeutics," he remarked further.

The second patent, 6,010,680, describes a general method of labeling of proteins with a radioisotope, providing a one-vial kit, and is especially useful for linking Cu-67, Hg-197, Pb-203, Ag-111, and Bi-212 to antibodies, drugs, cytokines, enzymes, hormones, and immune modulators.

"These patents provide us with proprietary methods to broaden our capabilities in developing novel therapeutic and imaging agents, particularly when linking these isotopes to disease-targeting proteins. Our first applications will be in cancer therapy, which is our Company's primary focus, and where we have a strong patent portfolio," Dr. Goldenberg stated.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. The Company's first product, CEA-Scan(R) for the detection of colorectal cancer, is being marketed in the United States and Europe (approved in Canada). The Company's second diagnostic imaging product, LeukoScan(R), is being marketed in Europe for the diagnosis of osteomyelitis (bone infection). Immunomedics also has several other diagnostic imaging products and three therapeutic products in clinical trials.

This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company's Annual Report on Form 10-K for the year ended June 30, 1999.

Company Contact: Cynthia L. Sullivan, Executive Vice President, 973-605-8200, extension 109. Visit Immunomedics' web site at http://www.Immunomedics.com.

SOURCE Immunomedics, Inc. >>

DB

Print the post Back To Top